Structure Based Drug Design
Mostrando 1-12 de 60 artigos, teses e dissertações.
-
1. Identification of Potential Inhibitors of Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Main Protease from Non-Natural and Natural Sources: A Molecular Docking Study
So far, there is neither a vaccine nor a specific antiviral drug to prevent or treat COVID-19 (coronavirus disease) infection. Recent studies have been done to investigate the capacity of human immunodeficiency virus type 1 (HIV-1) protease inhibitors be used in the treatment of COVID-19 patients. Some of those drugs have shown to be promising. Natural chemi
J. Braz. Chem. Soc.. Publicado em: 2020-12
-
2. Protein PEGylation for the design of biobetters: from reaction to purification processes
The covalent attachment of polyethylene glycol (PEG) to therapeutical proteins is an important route to develop biobetters for biomedical, biotech and pharmaceutical industries. PEG conjugation can shield antigenic epitopes of the protein, reduce degradation by proteolytic enzymes, enhance long-term stability and maintain or even improve pharmacokinetic and
Braz. J. Pharm. Sci.. Publicado em: 08/11/2018
-
3. Molecular Modeling, Structural Analysis and Evaluation of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) as a Putative Drug Target For Theileria Parva
ABSTRACT The apicomplexan parasite Theileria parva, the causative agent of ECF, is an important pathogen affecting both domestic and wild animals, causing major economic losses in the world. Problems such as high cost of drugs, development of resistance, and absence of effective vaccines prevent effective combating of the pathogen. Thus, it is necessary to e
Braz. arch. biol. technol.. Publicado em: 14/06/2018
-
4. From Medicinal Chemistry to Human Health: Current Approaches to Drug Discovery for Cancer and Neglected Tropical Diseases
ABSTRACT Scientific and technological breakthroughs have compelled the current players in drug discovery to increasingly incorporate knowledge-based approaches. This evolving paradigm, which has its roots attached to the recent advances in medicinal chemistry, molecular and structural biology, has unprecedentedly demanded the development of up-to-date comput
An. Acad. Bras. Ciênc.. Publicado em: 15/02/2018
-
5. Exploring the natural chemiome to target interleukin-6 receptor (IL-6R) cytokines: an atomic scale investigation for novel rheumatoid arthritis drug discovery
ABSTRACT Natural compounds are a gold mine for treating rheumatoid arthritis (RA). The etiology of this disease is linked to inflammation, where cytokines play an important role. Strategies have been drafted for targeting cytokines as a therapeutic option in patients with RA. Inhibiting cytokines with natural compounds has become a major focus for the develo
Braz. J. Pharm. Sci.. Publicado em: 01/02/2018
-
6. Liposomes as potential carriers for ketorolac ophthalmic delivery: formulation and stability issues
ABSTRACT Drug delivery to treat ocular disorders locally is a challenging endeavor. Traditional ocular dosage form - eye drops - exhibits poor availability, consequently inefficient therapeutic response. The objective of the study was to formulate and characterize a ketorolac tromethamine ocular system with a prolonged release pattern based on liposomes as a
Braz. J. Pharm. Sci.. Publicado em: 22/06/2017
-
7. Structure-based drug design studies of the interactions ofent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparumsarco/endoplasmic reticulum Ca2+-ATPase PfATP6
Malaria is responsible for more deaths around the world than any other parasitic disease. Due to the emergence of strains that are resistant to the current chemotherapeutic antimalarial arsenal, the search for new antimalarial drugs remains urgent though hampered by a lack of knowledge regarding the molecular mechanisms of artemisinin resistance. Semisynthet
Mem. Inst. Oswaldo Cruz. Publicado em: 2015-04
-
8. Structure-based drug design studies on a series of aldolase inhibitors
A tripanossomíase africana, também conhecida como doença do sono, é responsável por um grande número de mortes na África. Até o presente, não há tratamento seguro e eficaz disponível. A enzima aldolase do parasita Trypanosoma brucei é um alvo atrativo e validado para o desenvolvimento de novos fármacos. Uma série de ésteres fosfóricos foi est
J. Braz. Chem. Soc.. Publicado em: 2013-02
-
9. Identificação de novos inibidores da enzima cruzaína de Trypanosoma cruzi candidatos a fármacos contra a doença de Chagas / Discovery of novel inhibitors of the cruzain enzyme from Trypanosoma cruzi as drug candidates against Chagas disease
A doença de Chagas, uma infecção parasitária amplamente distribuída na América Latina, é um problema grave de saúde pública com consequências devastadoras em termos de morbidade e mortalidade humana. O arsenal terapêutico contra a doença é bastante limitado e insuficiente em todos os aspectos clínicos. Visando o desenvolvimento de novos agentes
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 30/07/2012
-
10. Planejamento de inibidores das enzimas diidroorotato desidrogenase de Trypanosoma cruzi e Leishmania major / Design of inhibitors for dihydroorotate dehydrogenase from Trypanosoma cruzi and Leishmania major
Dihydroorotate dehydrogenase (DHODH) catalyses the conversion of dihydroorote to orotate, the fourth step and only redox reaction in the de novo pyrimidine biosynthetic pathway. DHODH has been exploited as a validated target for therapy against proliferative and parasitic diseases, and in particular, has been considered to be an attractive target for drug de
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 25/04/2012
-
11. Planejamento de inibidores baseado em fragmentos moleculares para a enzima gliceraldeído-3-fosfato desidrogenase de Trypanosoma cruzi / Design of inhibitors through fragment-based drug discovery for the enzyme glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma cruzi
Chagas disease is a parasitic illness endemic in Latin America caused by the trypanosomatid parasite Trypanosoma cruzi that spreads around the world due to people migration. Nowadays, Benznidazole and Nifurtimox (banned in Brazil), are used for the treatment of this disease but causes severe side effects to patients. Recently, three new molecules have reache
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 20/04/2012
-
12. Modelagem molecular de uma série de compostos inibidores da enzima integrase do vírus HIV-1 / Molecular modelling for a series of integrase HIV-I inhibitors
An essential step in the HIV life cycle is integration of the viral DNA into the host chromosome. This step is catalyzed by a 32-kDa viral enzyme HIV integrase (IN). HIV-1 IN is an important and validated target, and the drugs that selectively inhibit this enzyme, when used in combination with reverse transcriptase (RT) and protease (PR) inhibitors, are beli
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 20/07/2011